<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02457182</url>
  </required_header>
  <id_info>
    <org_study_id>14-141</org_study_id>
    <nct_id>NCT02457182</nct_id>
  </id_info>
  <brief_title>Mindfulness-Based Therapy for Interstitial Cystitis/Bladder Pain Syndrome</brief_title>
  <official_title>Mindfulness-Based Therapy for Interstitial Cystitis/Bladder Pain Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of New Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interstitial cystitis/bladder pain syndrome (IC/BPS) is a poorly understood disease with
      unreliable treatments. Although it is not known what causes it for certain, we do know that
      life stressors may make the disease worse or cause flares. Mindfulness Based Stress Reduction
      (MBSR) is an 8 week class focused on meditation and other techniques that the investigators
      think may be helpful to people with IC/BPS. This trial will assign participants to an MBSR
      class or usual care for their IC/BPS to see if the MBSR class would be helpful for their
      disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND/SCIENTIFIC RATIONALE Interstitial cystitis/bladder pain syndrome (IC/BPS) is
      associated with significant morbidity and poorly understood underlying pathophysiology.
      IC/BPS comprises a symptom complex defined by the American Urological Association (AUA) as
      &quot;An unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary
      bladder, associated with lower urinary tract symptoms of more than six weeks duration, in the
      absence of infection or other identifiable causes&quot;(1). Up to 11% of women are affected by
      IC/BPS (2), and the disorder may be significantly underdiagnosed (3). A 2008 study (4)
      indicated that 43% of patients with IC/BPS require multimodal therapy with an average of 7-12
      yearly clinic visits at a cost of $9,000/patient. Twenty percent of women report wage losses
      of &gt;$4000 per year (5). Current theories for the cause of IC/BPS include infectious agents, a
      defective uroepithelium permeable to toxic substances, structural abnormalities, neurogenic
      inflammation, increased neurologic sensitivity, or an allergic response involving increased
      numbers of bladder mast cells (6). Despite these theories, reliable treatments remain
      elusive. Most IC/BPS treatments target one of these proposed mechanisms, involve trial and
      error of several therapies (1), and often utilize multiple modalities (7). Treatment success
      ranges from 47-93% for intravesical instillation to 21-64% for oral therapies, with
      discontinuation rates up to 80% due to intolerable side effects (1). Efficacious treatments
      for IC/BPS that apply to a greater proportion of patients with limited side effects are
      urgently needed.

      Mindfulness Based Stress Reduction (MBSR), a Complementary Alternative Medicine (CAM)-based
      therapy, potentially fulfills this need. The Interstitial Cystitis Association (ICA), a
      patient-led organization, sponsored a survey of 2100 IC/BPS patients. They reported that 84%
      had tried CAM therapy and 55% of those surveyed reported that their physicians had
      recommended CAM (8). According to a 2007 National Health Interview survey (9), CAM is used by
      38% of adults in the United States. MBSR has been successfully employed to treat chronic pain
      syndromes and has been used in disorders such as multiple chemical sensitivity, chronic
      fatigue syndrome, fibromyalgia (10), and irritable bowel syndrome (IBS) (11). These disorders
      may coexist in patients with IC/BPS (6). In IC/BPS, increases in stress are positively
      correlated with increased pain (12); and one study reported that up to 80% of IC/BPS patients
      found stress reduction decreased their symptoms (8). MBSR was found to be efficacious in the
      treatment of urgency urinary incontinence, a urinary disorder closely related to IC/BPS (13,
      14). While MBSR has shown therapeutic promise in conditions that are similar to or coexist
      with IC/BPS, and has been rated as helpful by patients suffering from IC/BPS, rigorous
      randomized clinical trials investigating the efficacy of this intervention are lacking (8).

      OBJECTIVES/AIMS/HYPOTHESES Ultimately, the investigators long-term goal is to provide a
      much-needed treatment for IC/BPS using patient-centered therapy such as MBSR. The objective
      of this research is to conduct a pilot RCT to explore whether MBSR is acceptable to patients
      and results in improved symptoms when added to IC/BPS 1st and 2nd-line treatments as
      recommended in the American Urological Association guidelines (see Table 1). The
      investigators hypothesize that an 8-week MBSR class will be acceptable to IC/BPS patients and
      that MBSR used in conjunction with traditional 1st and 2nd line therapies will improve
      symptoms compared to IC/BPS patients using traditional 1st and 2nd line therapies alone. If
      this pilot study demonstrates effectiveness and acceptance of MBSR, it would provide data to
      justify a larger randomized controlled trial. If the investigators' hypothesis is supported
      with this exploratory study, MBSR, an understudied and potentially underutilized therapy,
      will expand treatment options for IC/BPS patients. The investigators' aims in pursuit of this
      goal are; Aim #1: To determine whether the addition of MBSR to 1st and 2nd line therapies as
      recommended by AUA guidelines improves IC/BPS symptoms as measured by the primary outcome the
      Global Response Assessment (GRA), as well as the O'Leary-Sant Symptom and Problem Index
      (OSPI), and Visual Analog (VAS) pain scale. Hypothesis: The investigators hypothesize that
      MBSR will be an effective treatment for IC/BPS as measured by the validated GRA, O'Leary-Sant
      and VAS pain scales.

      Aim #2: To evaluate whether participation in a structured MBSR class will improve quality of
      life, sexual function and overall self-efficacy in patients with IC/BPS, based on changes in
      the Short Form Health Survey (SF-12), Female Sexual Function Index (FSFI), and the Pain
      Self-Efficacy Scale (SES). Hypothesis: The investigators' hypothesize that MBSR will improve
      quality of life, sexual function and impressions of self-efficacy as measured by these
      validated scales
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global Response Assessment (GRA)</measure>
    <time_frame>Within 2 weeks of 8-week class ending</time_frame>
    <description>The GRA is a 7-point scale, with scores ranging from markedly, moderately or slightly worse to slightly, moderately or markedly improved. This measure is used in many types of research and is not specific to IC/BPS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>O'Leary Sant Symptom Problem Index (OSPI)</measure>
    <time_frame>Baseline and within 2 weeks of 8-week class ending</time_frame>
    <description>The OSPI is a Interstitial cystitis (IC/BPS)-specific scale composed of the symptom index and problem index as well as a total, which sums the symptom and problem scores caused by IC/BPS.
Symptom scores range from 0-21. Problem scores range from 0-16 Higher scores indicate a worse condition. Total scores range 0-37, with higher scores indicating a worse condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog (VAS) Pain Scale</measure>
    <time_frame>Baseline and within 2 weeks of 8-week class ending</time_frame>
    <description>The VAS scale is a 10-point scale ranging from 0 (no pain) to 10 (unbearable pain). 0 is considered better while 10 is considered worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form Health Survey (SF-12)</measure>
    <time_frame>Baseline and within 2 weeks of 8-week class ending</time_frame>
    <description>The short form health survey (SF-12) is a scale used to evaluate chronic conditions. It is composed of a mental component and physical component. Each is made up of 12 questions totaling a score of 100 points. A zero score indicates the lowest level of health measured and 100 indicates the highest level of health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Female Sexual Function Index (FSFI)</measure>
    <time_frame>Baseline and within 2 weeks of 8-week class ending</time_frame>
    <description>The FSFI measures sexual function. It is composed of 6 individual domain scores (desire, arousal, lubrication, orgasm, satisfaction and pain), which are summed to create a total score. Higher scores indicate better sexual function.
Ranges:
Desire 2-10 Arousal 0-20 Lubrication 0-20 Orgasm 0-15 Satisfaction 2-15 Pain 0-15 Total score ranges from 4-95 and is calculated by adding the 6 domains together. Again, higher scores indicate better sexual function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Self-Efficacy Scale (PSEQ)</measure>
    <time_frame>Baseline and within 2 weeks of 8-week class ending</time_frame>
    <description>The PSEQ is a scale describing how patients rate their abilities to complete daily activities.
It is a 60 point scale (scores range from 0-60) composed of 10 questions. Higher numbers signify better functioning or less limit by disease. A total score is calculating by summing individual items.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Interstitial Cystitis</condition>
  <condition>Mindfulness</condition>
  <condition>Complementary Medicine</condition>
  <condition>Painful Bladder Syndrome</condition>
  <arm_group>
    <arm_group_label>Mindfulness-based Stress Reduction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mindfulness-based Stress Reduction (MBSR)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Usual medical therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mindfulness-based Stress Reduction (MBSR)</intervention_name>
    <arm_group_label>Mindfulness-based Stress Reduction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual medical therapy</intervention_name>
    <arm_group_label>Mindfulness-based Stress Reduction</arm_group_label>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Actively utilizing but are incomplete responders to the AUA guideline's 1st or 2nd
             line therapies

          -  Non-pregnant women ≥18 years old

          -  Meets IC/BPS diagnosis by AUA guidelines, OSPI &gt;8

          -  Negative UA or Urine Culture at time of diagnosis or within 2 months if no change in
             symptoms over that period

          -  Able to speak and understand English

          -  Currently undergoing 1st or 2nd-line treatment as per AUA guidelines, for at least 4
             weeks duration

        Exclusion Criteria:

          -  Untreated Urinary tract infection

          -  Unevaluated Hematuria

          -  Urinary retention

          -  Pregnant or lactating women

          -  History of cystectomy, augmentation cystoplasty or urinary diversion

          -  History of cystitis potentially due to pelvic radiation or Cytoxan

          -  Inability to speak and understand English

          -  Either treatment naïve for IC/BPS or on 3rd line or higher treatment per AUA
             guidelines
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Kanter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Urogynecology Fellow</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>January 8, 2015</study_first_submitted>
  <study_first_submitted_qc>May 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2015</study_first_posted>
  <results_first_submitted>June 3, 2016</results_first_submitted>
  <results_first_submitted_qc>January 2, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 9, 2018</results_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of New Mexico</investigator_affiliation>
    <investigator_full_name>Gregory Kanter</investigator_full_name>
    <investigator_title>Urogynecology Fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystitis</mesh_term>
    <mesh_term>Cystitis, Interstitial</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mindfulness-based Stress Reduction (MBSR)</title>
          <description>Received usual care continuing current treatments in addition to MBSR
Mindfulness-based Stress Reduction (MBSR)
Usual medical therapy</description>
        </group>
        <group group_id="P2">
          <title>Usual Care</title>
          <description>Received usual care and continue current treatments
Usual medical therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mindfulness-based Stress Reduction (MBSR)</title>
          <description>Will receive usual care continuing current treatments in addition to MBSR
Mindfulness-based Stress Reduction (MBSR)
Usual medical therapy</description>
        </group>
        <group group_id="B2">
          <title>Usual Care</title>
          <description>Will receive usual care and continue current treatments
Usual medical therapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.3" spread="15.2"/>
                    <measurement group_id="B2" value="44.4" spread="13.9"/>
                    <measurement group_id="B3" value="45.3" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time with IC diagnosis</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.0" spread="5.3"/>
                    <measurement group_id="B2" value="3.85" spread="5.1"/>
                    <measurement group_id="B3" value="4.3" spread="4.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time with IC symptoms</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.6" spread="9.9"/>
                    <measurement group_id="B2" value="8.9" spread="7.1"/>
                    <measurement group_id="B3" value="9.2" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (kg/m^2)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.0" spread="9.2"/>
                    <measurement group_id="B2" value="26.4" spread="6.0"/>
                    <measurement group_id="B3" value="27.1" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian/Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Global Response Assessment (GRA)</title>
        <description>The GRA is a 7-point scale, with scores ranging from markedly, moderately or slightly worse to slightly, moderately or markedly improved. This measure is used in many types of research and is not specific to IC/BPS.</description>
        <time_frame>Within 2 weeks of 8-week class ending</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mindfulness-based Stress Reduction (MBSR)</title>
            <description>Received usual care continuing current treatments in addition to MBSR
Mindfulness-based Stress Reduction (MBSR)
Usual medical therapy</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Received usual care and continue current treatments
Usual medical therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Global Response Assessment (GRA)</title>
          <description>The GRA is a 7-point scale, with scores ranging from markedly, moderately or slightly worse to slightly, moderately or markedly improved. This measure is used in many types of research and is not specific to IC/BPS.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Markedly Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least moderately improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least slightly improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>O'Leary Sant Symptom Problem Index (OSPI)</title>
        <description>The OSPI is a Interstitial cystitis (IC/BPS)-specific scale composed of the symptom index and problem index as well as a total, which sums the symptom and problem scores caused by IC/BPS.
Symptom scores range from 0-21. Problem scores range from 0-16 Higher scores indicate a worse condition. Total scores range 0-37, with higher scores indicating a worse condition.</description>
        <time_frame>Baseline and within 2 weeks of 8-week class ending</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mindfulness-based Stress Reduction (MBSR)</title>
            <description>Received usual care continuing current treatments in addition to MBSR
Mindfulness-based Stress Reduction (MBSR)
Usual medical therapy</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Received usual care and continue current treatments
Usual medical therapy</description>
          </group>
        </group_list>
        <measure>
          <title>O'Leary Sant Symptom Problem Index (OSPI)</title>
          <description>The OSPI is a Interstitial cystitis (IC/BPS)-specific scale composed of the symptom index and problem index as well as a total, which sums the symptom and problem scores caused by IC/BPS.
Symptom scores range from 0-21. Problem scores range from 0-16 Higher scores indicate a worse condition. Total scores range 0-37, with higher scores indicating a worse condition.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OSPI Total Before</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4" spread="8.1"/>
                    <measurement group_id="O2" value="25.4" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OSPI Total After</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9" spread="8.7"/>
                    <measurement group_id="O2" value="24.0" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OSPI Symptoms before</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" spread="5.3"/>
                    <measurement group_id="O2" value="15.2" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OSPI symptoms after</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="4.8"/>
                    <measurement group_id="O2" value="14.6" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OSPI Problems before</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="3.1"/>
                    <measurement group_id="O2" value="10.2" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OSPI Problems after</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="4.0"/>
                    <measurement group_id="O2" value="9.4" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog (VAS) Pain Scale</title>
        <description>The VAS scale is a 10-point scale ranging from 0 (no pain) to 10 (unbearable pain). 0 is considered better while 10 is considered worse.</description>
        <time_frame>Baseline and within 2 weeks of 8-week class ending</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mindfulness-based Stress Reduction (MBSR)</title>
            <description>Received usual care continuing current treatments in addition to MBSR
Mindfulness-based Stress Reduction (MBSR)
Usual medical therapy</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Received usual care and continue current treatments
Usual medical therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog (VAS) Pain Scale</title>
          <description>The VAS scale is a 10-point scale ranging from 0 (no pain) to 10 (unbearable pain). 0 is considered better while 10 is considered worse.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VAS Before</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="2.4"/>
                    <measurement group_id="O2" value="5.7" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS After</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="2.0"/>
                    <measurement group_id="O2" value="4.6" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Form Health Survey (SF-12)</title>
        <description>The short form health survey (SF-12) is a scale used to evaluate chronic conditions. It is composed of a mental component and physical component. Each is made up of 12 questions totaling a score of 100 points. A zero score indicates the lowest level of health measured and 100 indicates the highest level of health.</description>
        <time_frame>Baseline and within 2 weeks of 8-week class ending</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mindfulness-based Stress Reduction (MBSR)</title>
            <description>Received usual care continuing current treatments in addition to MBSR
Mindfulness-based Stress Reduction (MBSR)
Usual medical therapy</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Received usual care and continue current treatments
Usual medical therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Short Form Health Survey (SF-12)</title>
          <description>The short form health survey (SF-12) is a scale used to evaluate chronic conditions. It is composed of a mental component and physical component. Each is made up of 12 questions totaling a score of 100 points. A zero score indicates the lowest level of health measured and 100 indicates the highest level of health.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MCS Before</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0" spread="4.5"/>
                    <measurement group_id="O2" value="36.6" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCS After</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.0" spread="8.9"/>
                    <measurement group_id="O2" value="40.8" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCS Before</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5" spread="8.6"/>
                    <measurement group_id="O2" value="44.1" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCS After</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.3" spread="10.3"/>
                    <measurement group_id="O2" value="46.5" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Female Sexual Function Index (FSFI)</title>
        <description>The FSFI measures sexual function. It is composed of 6 individual domain scores (desire, arousal, lubrication, orgasm, satisfaction and pain), which are summed to create a total score. Higher scores indicate better sexual function.
Ranges:
Desire 2-10 Arousal 0-20 Lubrication 0-20 Orgasm 0-15 Satisfaction 2-15 Pain 0-15 Total score ranges from 4-95 and is calculated by adding the 6 domains together. Again, higher scores indicate better sexual function.</description>
        <time_frame>Baseline and within 2 weeks of 8-week class ending</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mindfulness-based Stress Reduction (MBSR)</title>
            <description>Received usual care continuing current treatments in addition to MBSR
Mindfulness-based Stress Reduction (MBSR)
Usual medical therapy</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Received usual care and continue current treatments
Usual medical therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Female Sexual Function Index (FSFI)</title>
          <description>The FSFI measures sexual function. It is composed of 6 individual domain scores (desire, arousal, lubrication, orgasm, satisfaction and pain), which are summed to create a total score. Higher scores indicate better sexual function.
Ranges:
Desire 2-10 Arousal 0-20 Lubrication 0-20 Orgasm 0-15 Satisfaction 2-15 Pain 0-15 Total score ranges from 4-95 and is calculated by adding the 6 domains together. Again, higher scores indicate better sexual function.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Desire before</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="1.6"/>
                    <measurement group_id="O2" value="2.7" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Desire after</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="1.6"/>
                    <measurement group_id="O2" value="2.6" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arousal before</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="2.1"/>
                    <measurement group_id="O2" value="2.0" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arousal after</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="2.3"/>
                    <measurement group_id="O2" value="2.3" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lubrication before</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="2.7"/>
                    <measurement group_id="O2" value="1.6" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lubrication after</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="2.4"/>
                    <measurement group_id="O2" value="3.1" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Orgasm before</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="2.7"/>
                    <measurement group_id="O2" value="2.2" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Orgasm after</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="2.5"/>
                    <measurement group_id="O2" value="2.3" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction before</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="2.3"/>
                    <measurement group_id="O2" value="2.8" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction after</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="1.9"/>
                    <measurement group_id="O2" value="3.4" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain before</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="2.4"/>
                    <measurement group_id="O2" value="2.1" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain after</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="2.6"/>
                    <measurement group_id="O2" value="2.8" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total before</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="12.8"/>
                    <measurement group_id="O2" value="13.8" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total after</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" spread="12.0"/>
                    <measurement group_id="O2" value="16.4" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Self-Efficacy Scale (PSEQ)</title>
        <description>The PSEQ is a scale describing how patients rate their abilities to complete daily activities.
It is a 60 point scale (scores range from 0-60) composed of 10 questions. Higher numbers signify better functioning or less limit by disease. A total score is calculating by summing individual items.</description>
        <time_frame>Baseline and within 2 weeks of 8-week class ending</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mindfulness-based Stress Reduction (MBSR)</title>
            <description>Received usual care continuing current treatments in addition to MBSR
Mindfulness-based Stress Reduction (MBSR)
Usual medical therapy</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Received usual care and continue current treatments
Usual medical therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Self-Efficacy Scale (PSEQ)</title>
          <description>The PSEQ is a scale describing how patients rate their abilities to complete daily activities.
It is a 60 point scale (scores range from 0-60) composed of 10 questions. Higher numbers signify better functioning or less limit by disease. A total score is calculating by summing individual items.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PSEQ Before</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.3" spread="4.5"/>
                    <measurement group_id="O2" value="30.8" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSEQ After</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.8" spread="4.9"/>
                    <measurement group_id="O2" value="33.5" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Mindfulness-based Stress Reduction (MBSR)</title>
          <description>Received usual care continuing current treatments in addition to MBSR
Mindfulness-based Stress Reduction (MBSR)
Usual medical therapy</description>
        </group>
        <group group_id="E2">
          <title>Usual Care</title>
          <description>Received usual care and continue current treatments
Usual medical therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gregg Kanter, MD</name_or_title>
      <organization>University of New Mexico</organization>
      <phone>818-599-3456</phone>
      <email>greggkanter@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

